Acquisition - September 22, 2015
Division by Zero acquired by Brighter
The acquisition of Division By Zero AB expands Brighter’s IP portfolio with unique technology for, among other things, feedback human response to targeted stimuli. Brighter has offered to acquire 100% stake in Division By Zero through a share issue equivalent to 2.70 shares in Brighter per 1 share in Division By Zero. With the support […]
Acquisition - September 3, 2015
Novo to Acquire Calibrium and MB2
Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies. The two companies are based in Indiana, US, and Novo Nordisk’s acquisition will expand the company portfolio within diabetes and obesity. Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment […]
Acquisition - September 3, 2015
Karo Bio acquires Apropharm
Karo Bio io AB has announced today that it has acquired the two companies Apropharm AS and Apropharm AB. The product portfolio consists of mainly pharmaceutical products in Norway and Sweden. A newly registred product for soar throat, Triolif, has recently become registred and will be launched in September. The turnover is approximately 50 MSEK with a operating profit […]
Acquisition - August 26, 2015
Recipharm signs agreement with RedHill Biopharma
Recipharm has announces that it has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105. RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion. Recipharm will be responsible for the supply […]
Acquisition - August 12, 2015
Alligator Bioscience in billion-dollar business deal
Janssen Biotech, one of the Janssen pharmaceutical companies of Johnson & Johnson has entered an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies. Under terms of the agreement, Janssen will attain rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody. ADC-1013 targets […]
Acquisition - July 7, 2015
Navamedic acquires Observe Medical
The Norwegian company Navamedic, a specialty pharmaceutical company, has acquired the Swedish medtech company Observe Medical. The initial purchase price is NOK 35 million, with additional payments dependent on performance in the coming years. Observe Medical has developed an automated, digital urine meter Sippi for use in intensive care wards. The product was launced in […]
